Fintel reports that on January 10, 2025, Maxim Group upgraded their outlook for Reviva Pharmaceuticals Holdings ...

In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

Agreement grants Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet ...

About ADARx Pharmaceuticals ADARx Pharmaceuticals, Inc. is a late-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide ...

NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

The FDA has granted Cour Pharmaceuticals orphan drug designation for CNP-104, a biodegradable nanoparticle in development for ...